JRC Publications Repository

JRC Publications Repository >

Browsing by Author APOSTOLIDIS Christos

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:   
Sort by: In order: Results/Page Authors/Record:
Showing results 86 to 105 of 147
Publication YearTitleAuthor(s), Editor(s), Other Contributor(s)Publication Type
2012Orthotopic administration of 213Bi-Bevacizumab inhibits progression of PC3 xenografts in the prostateRIZVI S.m.a.; ALLEN B.j.; LEE C.s.; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; APOSTOLIDIS Christos; CLARKE R.a.Articles in Journals
1996Oxo-Bridged Bimetallic Organouranium Complexes. The Crystal Structure of nu-Oxo-Bis[Tris(Cyclopentadienyl)Uranium]SPIRLET M.r.; REBIZANT Jean; APOSTOLIDIS Christos; DORNBERGER Ernst; POWIETZKA B.Articles in Journals
2007Pharmacokinetics and toxicity of 213Bi-labeled PAI2 in Preclinical Targeted Alpha Therapy for CancerSONG E.; ABBAS RIZVI S. M.; QU C. F.; RAJA C.; BRECHBIEL M. W.; MORGENSTERN ALFRED; APOSTOLIDIS CHRISTOS; ALLEN B. J.Articles in Journals
2014A plutonium-based single-molecule magnetMAGNANI Nicola; COLINEAU Eric; GRIVEAU Jean-Christophe; APOSTOLIDIS Christos; WALTER OLAF; CACIUFFO RobertoArticles in Journals
2005Pre-clinical Study of 213Bi Labeled PAI2 for the Control of Micrometastatic Pancreatic CancerQU C.f.; SONG E.; LI Y.; RIZVI S.m.a.; RAJA C.; ROSS R; APOSTOLIDIS CHRISTOS; ALLEN Barry J.; MORGENSTERN ALFREDArticles in Journals
2006Preclinical Studies of Bismuth-213 Labeled Plasminogen Activator Inhibitor Type 2 (PAI2) in a Prostate Cancer Nude Mouse Xenograft ModelRIZVI S.m.a.; LI Y.; SONG E.; QU C.f.; RAJA C.; MORGENSTERN ALFRED; APOSTOLIDIS CHRISTOS; ALLEN B.j.Articles in Journals
2008Preparation and Testing of Bevacizumab Radioimmunoconjugates with Bismuth-213 and Bismuth-205 / Bismuth-206RIZVI S.; SONG E.; RAJA C.; BERETOV J.; MORGENSTERN Alfred; APOSTOLIDIS Christos; RUSSELL P. J.; KEARSLEY J.; ABBAS Kamel; ALLEN B. J.Articles in Journals
2008Production of 230U/226Th for Targeted Alpha Therapy via Proton Irradiation of 231PaMORGENSTERN Alfred; LEBEDA O.; STURSA J.; BRUCHERTSEIFER Frank; CAPOTE R.; MCGINLEY John; RASMUSSEN Gert; SIN M.; ZIELINSKA B.; APOSTOLIDIS ChristosArticles in Journals
1998Production of Ac-225 and Application of the Bi-213 Daughter in Cancer Therapy.KOCH Lothar; APOSTOLIDIS Christos; JANSSENS Willem; VAN GEEL Jacobus; MOLINET RogerContributions to Conferences
2005Production of Ac-225 from Th-229 for Targeted Alpha TherapyAPOSTOLIDIS CHRISTOS; MOLINET Roger; MORGENSTERN ALFREDArticles in Journals
2008Production of Alpha Emitters for Targeted Alpha TherapyMORGENSTERN Alfred; ABBAS Kamel; BRUCHERTSEIFER Frank; APOSTOLIDIS ChristosArticles in Journals
2008Production of Alpha Emitting Radionuclides for Nuclear MedicineMORGENSTERN Alfred; APOSTOLIDIS Christos; BRUCHERTSEIFER FrankArticles in books
2001Production of Carrier Free Actinium-225/Bismuth-212 from Thorium-229 for alpha-Immunitherapy.APOSTOLIDIS Christos; BETTI Maria; CARLOS-MARQUEZ R.; JANSSENS Willem; MOLINET Roger; NIKULA T.; QUADI AliContributions to Conferences
2009Radioimmunotherapy of Breast Cancer Metastases with Alpha-Particle-emitter 225Ac: Comparing Efficacy with 213Bi, 90YSONG Hong; HOBBS Robert F.; VAJRAVELU Ravy; HUSO David L.; ESAIAS Caroline; APOSTOLIDIS Christos; MORGENSTERN Alfred; SGOUROS GeorgeArticles in Journals
2009Radioimmunotherapy of human bladder cancer in a nude mouse model comparing Bi-213-anti-EGFR-MAb and Th-226-anti-EGFR-MAbPFOST B.; MORGENSTERN Alfred; SEIDL C.; BRUCHERTSEIFER Frank; AUTENRIETH M.; APOSTOLIDIS Christos; ABBAS Kamel; SENEKOWITSCH-SCHMIDTKE R.Contributions to Conferences
2001Radiopeptide Therapy with Cholecystokinin(CCK)-B/Gastrin Receptor Ligands Labeled with Auger/Conversion Electron-versus alpha- or Conventional beta Emitters.BEHR T.m.; BEHE M.; ANGERSTEIN C.; STABIN M.g.; APOSTOLIDIS Christos; MOLINET Roger; KOCH Lothar; ROESCH F.; BECKER W.Contributions to Conferences
2000Radiopeptide Therapy with Cholecystokinin-B/Gastrin Receptor Ligands: Dose-Limiting Toxicity and Therapeutic Efficacy of Auger / Conversion Electron (111-In, 140-Nd) vs alpha(213-Bi) or Conventional beta(90-Y, 153-Sm) Emitters.BEHR T.m.; BEBE M.; STABIN M.g.; ANGERSTEIN C.; MACH R.; HAGEMANN L.; APOSTOLIDIS Christos; MOLINET Roger; KOCH Lothar; ROESCH F., et alContributions to Conferences
2012Reduction of Pu(VI) by FeCARBOL Paul; WEGEN Detlef; WISS Thierry; JANSSEN ARNE; NICHOLL Adrian; CREMER Bert; MALMBECK Rikard; VAN WINCKEL Stefaan; APOSTOLIDIS Christos; ALVAREZ SARANDES LAVANDERA Rafael, et alContributions to Conferences
2001Separation of 248Cm from a 252Cf Neutron Source for Production of Cm Targets.MALMBECK R.; APOSTOLIDIS Christos; CARLOS R.; GLATZ Jean paul; MOLINET Roger; MORGENSTERN A.; NICHOLL Adrian felim; PAGLIOSA G.; ROEMER K.; SCHAEDEL M., et alArticles in Journals
2004Sequential Therapy with Cytarabine and Bismuth-213 (213BI)-Labeled-HuM195(Anit-CD33) for Acute Myeloid Leukemia (AML).MULFORD D.a.; PANDIT-TASKAR N.; MC DEVITT M.r.; FINN R.d.; APOSTOLIDIS Christos; MORGENSTERN A.; DIVGI C.r.; LARSON S.m.; SCHEINBERG D.a.; JURCIC J.g.Contributions to Conferences
Showing results 86 to 105 of 147

 

The mission of the JRC is to provide customer-driven scientific and technical support for the conception, development, implementation and monitoring of EU policies. As a service of the European Commission, the JRC functions as a reference centre of science and technology for the Union. Close to the policy-making process, it serves the common interest of the Member States, while being independent of special interests, whether private or national.
Powered by DSpace
Top